Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes

NCT01601990 | Completed Phase 3

• 1 other identifier: LG-DPCL005
• Study Type: interventional
• Target: 189
• Locations: 1 country
• Sites: 1

Brief Summary

Double-blind, randomized, multicenter, multinational (South Korea and India), parallel group study The study was divided into three parts: part 1 was started with an initial 2 weeks of exercise/diet program followed by another 2 weeks of single-blind placebo run-in period; part 2 was a double-blind treatment period during which eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks; part 3 was for those patients who completed part 1 \& 2 and consented to receive another 28 weeks of treatment with LC15-0444 50mg. Screening tests were performed on the patients who had given the written informed consent. After 2-week exercise/diet program according to the generally recognized guideline, patients took placebo for another 2 weeks while continuing exercise/diet program. When the 2-week placebo run-in period was completed, eligible patients were assigned either to placebo or 50 mg of LC15-0444 with 1:1 ratio. During the total of 24- week treatment period of part 2 after randomization, each patient visited the investigational site at Week 6, 12, 18, and 24. Completing treatment with placebo or LC15-0444 50mg for 24 weeks after randomization, each patient was asked to provide consent to participate in the part 3 of the study where all the patients were to receive LC15-0444 50mg regardless of the treatment received during the part 2 of the study. During 28-week treatment period of the part 3, each patient visited the investigational site at Week 30, 38, 46, and 52. Total study period from screening was 56 weeks per each patient.

Conditions

Type 2 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Change of HbAlc

  from baseline to Week 24

Secondary Outcomes (1)

• HbA1c Responder Rate

  at Week 24

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Drug: Placebo group(once daily)

LC15-0444

EXPERIMENTAL

Drug: LC15-0444 50mg qd

Interventions

Placebo group(once daily) DRUG

eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.

Placebo

LC15-0444 50mg qd DRUG

eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks

LC15-0444

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with Type 2 Diabetes Mellitus
• Adults between 18 and 75 of age
• Patients with HbA1c between 7 % and 11 %
• Patient who had not received any diabetic medications within 6 weeks from screening
• Patients who signed on the consent form after informed on the object, method, and risks of the clinical study

You may not qualify if:

• Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes
• Patients who were taking or needed to take any drugs which may affect the control of blood glucose significantly (ex. glucocorticoids)
• Patients who had experienced myocardial infarction, unstable angina or prior history of coronary artery bypass surgery within 6 months prior to screening, or patients with arrhythmia requiring treatment
• Patients with NYHA class II-IV congestive heart failure
• Patients with history of hepatic cirrhosis
• Patients with renal failure or whose creatinine clearance was less than 60mL/min
• Patients with dysfunctional thyroid gland (with abnormal level of TSH)
• Patients with ALT, AST or CPK exceeding 2.5 times of the upper limit of the normal range
• Patients with BMI below 20 kg/m2 or exceeding 40 kg/m2
• Patients with history of asthma or major skin allergy
• Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.
• Patients with history of hypersensitivity to metformin or biguanides.
• Patients who took sodium channel blockers in the last 6 weeks prior to Visit 1.
• Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or who took thiazolidinediones (Glitazone) in the last 6 months prior to Visit 1.
• Patients with other reasons who the investigator decided not to be eligible for the study

Sponsors & Collaborators

• LG Life Sciences: lead

Study Sites (1)

LG Life Sciences

Seoul, 110-062, South Korea

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

LC15-0444

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Se Hyun Baek, MD, PhD

  Korea University Guro Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2012
• First Posted: May 18, 2012
• Study Start: December 1, 2009
• Primary Completion: March 1, 2011
• Study Completion: November 1, 2011
• Last Updated: May 18, 2012

Record last verified: 2012-05

Locations

KR (1)